Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches

Phase II Studies Failed For IL-2 Mutein, LPAR1 Agonist

 
• By Mandy Jackson
  
Amgen also moved MariTide into a Phase II study in type 2 diabetes (Shutterstock)

More from Earnings

More from Scrip